Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Jun 26;14(6):e078358.
doi: 10.1136/bmjopen-2023-078358.

Impella versus VA-ECMO for the treatment of patients with cardiogenic shock: the Impella Network Project - observational study protocol for cost-effectiveness and budget impact analyses

Affiliations
Comparative Study

Impella versus VA-ECMO for the treatment of patients with cardiogenic shock: the Impella Network Project - observational study protocol for cost-effectiveness and budget impact analyses

Vittoria Ardito et al. BMJ Open. .

Abstract

Introduction: The treatment of patients with cardiogenic shock (CS) encompasses several health technologies including Impella pumps and venoarterial extracorporeal membrane oxygenation (VA-ECMO). However, while they are widely used in clinical practice, information on resource use and quality of life (QoL) associated with these devices is scarce. The aim of this study is, therefore, to collect and comparatively assess clinical and socioeconomic data of Impella versus VA-ECMO for the treatment of patients with severe CS, to ultimately conduct both a cost-effectiveness (CEA) and budget impact (BIA) analyses.

Methods and analysis: This is a prospective plus retrospective, multicentre study conducted under the scientific coordination of the Center for Research on Health and Social Care Management of SDA Bocconi School of Management and clinical coordination of Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute in Milan. The Impella Network stemmed for the purposes of this study and comprises 17 Italian clinical centres from Northern to Southern Regions in Italy. The Italian network qualifies as a subgroup of the international Impella Cardiac Surgery Registry. Patients with CS treated with Impella pumps (CP, 5.0 or 5.5) will be prospectively recruited, and information on clinical outcomes, resource use and QoL collected. Economic data will be retrospectively matched with data from comparable patients treated with VA-ECMO. Both CEA and BIA will be conducted adopting the societal perspective in Italy. This study will contribute to generate new socioeconomic evidence to inform future coverage decisions.

Ethics and dissemination: As of May 2024, most of the clinical centres submitted the documentation to their ethical committee (N=13; 76%), six centres received ethical approval and two centres started to enrol patients. Study results will be published in peer-reviewed publications and disseminated through conference presentations.

Keywords: cardiology; health economics; observational study.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. McDonagh TA, Metra M, Adamo M, et al. . ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–726. 10.1093/eurheartj/ehab368 - DOI - PubMed
    1. Pahuja M, Hernandez-Montfort J, Whitehead EH, et al. . Device profile of the Impella 5.0 and 5.5 system for mechanical circulatory support for patients with cardiogenic shock: overview of its safety and efficacy. Expert Rev Med Devices 2022;19:1–10. 10.1080/17434440.2022.2015323 - DOI - PubMed
    1. Cohen WG, Rekhtman D, Iyengar A, et al. . Extended support with the Impella 5.5: transplant, ECMO, and complications. ASAIO J 2023;69:642–8. 10.1097/MAT.0000000000001931 - DOI - PubMed
    1. Schultz J, Duval S, Shaffer A, et al. . Axillary or Subclavian Impella 5.0 support in cardiogenic shock: A systematic review and meta-analysis. ASAIO J 2022;68:233–8. 10.1097/MAT.0000000000001452 - DOI - PubMed
    1. Bernhardt AM, Potapov E, Schibilsky D, et al. . First in man evaluation of a novel circulatory support device: early experience with the Impella 5.5 after CE mark approval in Germany. J Heart Lung Transplant 2021;40:850–5. 10.1016/j.healun.2021.04.001 - DOI - PubMed

Publication types

LinkOut - more resources